Central nervous system thrombosis in pediatric acute lymphoblastic leukemia in Turkey: A multicenter study

Simple item page
dc.contributor.authorGuzelkucuk Z.
dc.contributor.authorKarapınar D.Y.
dc.contributor.authorGelen S.A.
dc.contributor.authorTokgoz H.
dc.contributor.authorOzcan A.
dc.contributor.authorAy Y.
dc.contributor.authorBahadır A.
dc.contributor.authorOzbek N.Y.
dc.contributor.authorOren A.C.
dc.contributor.authorAyhan A.C.
dc.contributor.authorAkyay A.
dc.contributor.authorAkıncı B.
dc.contributor.authorKaradas N.
dc.contributor.authorUnuvar A.
dc.contributor.authorOren H.
dc.contributor.authorFettah A.
dc.contributor.authorKaya Z.
dc.contributor.authorIsık B.
dc.contributor.authorEker İ.
dc.contributor.authorKaraman S.
dc.contributor.authorYıldırım A.T.
dc.contributor.authorOrhan M.F.
dc.contributor.authorOymak Y.
dc.contributor.authorTimur C.
dc.contributor.authorYazici N.
dc.contributor.authorSimsek A.
dc.contributor.authorKarakurt N.
dc.contributor.authorToret E.
dc.contributor.authorEvim M.S.
dc.date.accessioned2024-07-22T08:02:41Z
dc.date.available2024-07-22T08:02:41Z
dc.date.issued2023
dc.description.abstractBackground: In patients with acute lymphoblastic leukemia (ALL), the risk of thromboembolism increases due to hemostatic changes secondary to the primary disease and due to treatment-related factors. In this multicenter study, we aimed to research the frequency of central nervous system (CNS) thrombosis occurring during treatment, hereditary and acquired risk factors, clinical and laboratory features of patients with thrombosis, treatment approaches, and thrombosis-related mortality and morbidity rates in pediatric ALL patients. Procedure: Pediatric patients who developed CNS thrombosis during ALL treatment from 2010 to 2021 were analyzed retrospectively in 25 different Pediatric Hematology Oncology centers in Türkiye. The demographic characteristics of the patients, symptoms associated with thrombosis, the stage of the leukemia treatment during thrombosis, the anticoagulant therapy applied for thrombosis, and the final status of the patients recorded through electronic medical records were determined. Results: Data from 70 patients with CNS thrombosis during treatment, out of 3968 pediatric patients with ALL, were reviewed. The incidence of CNS thrombosis was 1.8% (venous: 1.5 %; arterial: 0.03%). Among patients with CNS thrombosis, 47 had the event in the first 2 months. Low molecular weight heparin (LMWH) was the most commonly used treatment with a median of 6 months (min–max: 3–28 months). No treatment-related complications occurred. Chronic thrombosis findings occurred in four patients (6%). In five (7%) patients who developed cerebral vein thrombosis, neurological sequelae (epilepsy and neurological deficit) remained. One patient died related to thrombosis, and the mortality rate was 1.4%. Conclusion: Cerebral venous thrombosis and, less frequently, cerebral arterial thrombosis may develop in patients with ALL. The incidence of CNS thrombosis is higher during induction therapy than during other courses of treatment. Therefore, patients receiving induction therapy should be monitored carefully for clinical findings suggestive of CNS thrombosis. © 2023 Wiley Periodicals LLC.
dc.identifier.DOI-ID10.1002/pbc.30425
dc.identifier.issn15455009
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11965
dc.language.isoEnglish
dc.publisherJohn Wiley and Sons Inc
dc.subjectCentral Nervous System
dc.subjectChild
dc.subjectHeparin, Low-Molecular-Weight
dc.subjectHumans
dc.subjectPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subjectRetrospective Studies
dc.subjectThrombosis
dc.subjectTurkey
dc.subjectlow molecular weight heparin
dc.subjectacute lymphoblastic leukemia
dc.subjectadolescent
dc.subjectanticoagulant therapy
dc.subjectartery thrombosis
dc.subjectArticle
dc.subjectbrain vein
dc.subjectcancer staging
dc.subjectcentral nervous system disease
dc.subjectchild
dc.subjectchronic disease
dc.subjectclinical feature
dc.subjectconsciousness disorder
dc.subjectconvulsion
dc.subjectdeath
dc.subjectdemographics
dc.subjectdisease association
dc.subjectdizziness
dc.subjectelectronic medical record
dc.subjectepilepsy
dc.subjectfacial nerve paralysis
dc.subjectfemale
dc.subjectfrequency
dc.subjectgenetic disorder
dc.subjectgenetic risk
dc.subjectheadache
dc.subjecthemiparesis
dc.subjecthuman
dc.subjectincidence
dc.subjectinfant
dc.subjectlaboratory test
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmorbidity
dc.subjectmortality
dc.subjectmortality rate
dc.subjectmulticenter study
dc.subjectneurologic disease
dc.subjectnewborn
dc.subjectparesthesia
dc.subjectpersonality disorder
dc.subjectretrospective study
dc.subjectrisk factor
dc.subjectspeech disorder
dc.subjectthrombophilia
dc.subjectTurkey (republic)
dc.subjectvein thrombosis
dc.subjectvisual impairment
dc.subjectvomiting
dc.subjectweakness
dc.subjectacute lymphoblastic leukemia
dc.subjectcentral nervous system
dc.subjectclinical trial
dc.subjectcomplication
dc.subjectthrombosis
dc.subjectturkey (bird)
dc.titleCentral nervous system thrombosis in pediatric acute lymphoblastic leukemia in Turkey: A multicenter study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu